Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech company Exelixis (NASDAQ:EXEL) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Exelixis and see what CAPS investors are saying about the stock right now.

Exelixis facts

Headquarters (founded)

South San Francisco, Calif. (1994)

Market Cap

$837.8 million

Industry

Biotechnology

Trailing-12-Month Revenue

$47.5 million

Management

Co-Founder/Chairman Dr. Stelios Papadopoulos
President/CEO Dr. Michael Morrissey

Trailing-12-Month Return on Equity

(76.3%)

Cash/Debt

$411.4 million / $335.7 million

Competitors

AstraZeneca
Genentech
GlaxoSmithKline

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 96% of the 2,642 members who have rated Exelixis believe the stock will outperform the S&P 500 going forward.

Just last week, one of those Fools, JoeArizona, succinctly summed up the Exelixis bull case for our community:

Clinical trials are ongoing, and I don't anticipate much growth until the current round of trials show conclusive evidence that Cabozantinib is effective. But they already have one FDA approval under their belt, and as more come in the next few years, [Exelixis] will take off.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Exelixis. The Motley Fool owns shares of Exelixis. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.